Rafael (NYSE:RFL) Shares Down 3.3% – Here’s Why

Rafael Holdings, Inc. (NYSE:RFL)’s stock price fell 3.3% during trading on Thursday . The stock traded as low as $1.31 and last traded at $1.3250. 21,537 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 76,690 shares. The stock had previously closed at $1.37.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Rafael from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Rafael has a consensus rating of “Sell”.

Rafael Trading Up 0.3%

The company’s 50-day simple moving average is $1.28 and its 200-day simple moving average is $1.27. The stock has a market capitalization of $69.38 million, a price-to-earnings ratio of -1.69 and a beta of 0.50.

Rafael (NYSE:RFL) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.13) earnings per share (EPS) for the quarter. Rafael had a negative net margin of 2,846.60% and a negative return on equity of 37.27%. The business had revenue of $0.21 million during the quarter.

Institutional Investors Weigh In On Rafael

Several large investors have recently modified their holdings of the company. Renaissance Technologies LLC increased its position in shares of Rafael by 59.1% during the first quarter. Renaissance Technologies LLC now owns 89,138 shares of the company’s stock worth $111,000 after buying an additional 33,111 shares during the period. Geode Capital Management LLC boosted its stake in Rafael by 25.4% during the fourth quarter. Geode Capital Management LLC now owns 445,866 shares of the company’s stock worth $526,000 after acquiring an additional 90,417 shares in the last quarter. Citadel Advisors LLC boosted its stake in Rafael by 132.3% during the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after acquiring an additional 41,335 shares in the last quarter. Vanguard Group Inc. boosted its stake in Rafael by 10.5% during the third quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock worth $1,897,000 after acquiring an additional 133,024 shares in the last quarter. Finally, Cable Car Capital LP bought a new position in Rafael during the second quarter worth $173,000. 11.30% of the stock is currently owned by institutional investors and hedge funds.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.